Author Archives: truemeds

Selatinib is an emerging dual tyrosine kinase inhibitor (TKI) targeting EGFR and HER2, two critical oncogenic drivers in cancers such as HER2-positive breast and gastric cancers. As a structurally optimized analog of lapatinib, Selatinib offers improved pharmacokinetics, reduced toxicity, and promising antitumor activity. Early clinical trials have demonstrated its safety and bioavailability, while preclinical data […]

AMPK and Autophagy: AMP-activated protein kinase (AMPK) is a central energy sensor that plays a pivotal role in maintaining cellular homeostasis, especially during metabolic stress. One of its most critical functions is the regulation of autophagy—a self-degradative process essential for clearing damaged organelles, misfolded proteins, and other cellular debris. This blog explores the structure and […]

Rufinamide is an antiepileptic drug primarily used as adjunctive therapy for managing seizures associated with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsy. It works by modulating voltage-gated sodium channels, stabilizing abnormal electrical activity in the brain. Rufinamide has demonstrated significant efficacy in reducing seizure frequency, particularly drop attacks, and is generally well tolerated […]

Ritlecitinib for Alopecia Areata is a first-in-class, oral JAK3 and TEC kinase inhibitor recently approved by the FDA for the treatment of severe alopecia areata in both adults and adolescents. Unlike traditional therapies, Ritlecitinib offers targeted immunomodulation by selectively disrupting key cytokine signaling pathways responsible for autoimmune hair follicle attack. Clinical trials have demonstrated significant […]

Decoding Cancer Epigenetics: Recent advances in epitranscriptomics have revealed that RNA modifications, particularly N6-methyladenosine (m6A), play crucial roles in regulating gene expression beyond the DNA level. At the heart of this regulation are YTH domain-containing proteins, the primary “readers” of m6A marks. These proteins orchestrate key post-transcriptional processes such as mRNA splicing, translation, export, and […]

Diabetic microvascular complications—including nephropathy, retinopathy, and neuropathy—remain a major cause of morbidity despite advances in blood glucose control. Emerging evidence identifies Protein Kinase C (PKC) as a central driver of vascular dysfunction in diabetes, activated by chronic hyperglycemia and oxidative stress. This blog explores the molecular role of PKC isoforms in disease progression, highlighting their […]

Obestatin is a lesser-known peptide hormone derived from the same gene as ghrelin but with potentially opposite or complementary functions. Though initially thought to suppress appetite, recent research highlights obestatin’s broader role in human health, including glucose metabolism, pancreatic β-cell protection, cardiovascular regulation, and anti-inflammatory effects. Its actions extend into areas of obesity, diabetes, and […]

RAS Mutations in Cancer: RAS mutations represent one of the most frequent and challenging oncogenic drivers in human cancers, historically considered “undruggable” due to their structural and biochemical properties. However, recent advances have revolutionized this landscape. This blog explores the biology of RAS signaling, its clinical implications, and the emergence of targeted therapies such as […]